Ligand Pharmaceuticals Incorporated LGDN.F Stock
Ligand Pharmaceuticals Incorporated Price Chart
Ligand Pharmaceuticals Incorporated LGDN.F Financial and Trading Overview
Ligand Pharmaceuticals Incorporated stock price | 76 EUR |
Previous Close | 71 EUR |
Open | 72 EUR |
Bid | 71.5 EUR x 10000 |
Ask | 72.5 EUR x 10000 |
Day's Range | 72 - 72 EUR |
52 Week Range | 54.47 - 105.15 EUR |
Volume | 30 EUR |
Avg. Volume | 1 EUR |
Market Cap | 1.28B EUR |
Beta (5Y Monthly) | 0.970422 |
PE Ratio (TTM) | 26.086956 |
EPS (TTM) | 2.83 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 207.86 EUR |
LGDN.F Valuation Measures
Enterprise Value | 1.02B EUR |
Trailing P/E | 26.086956 |
Forward P/E | 17.910448 |
PEG Ratio (5 yr expected) | 1.57 |
Price/Sales (ttm) | 6.260573 |
Price/Book (mrq) | 1.908751 |
Enterprise Value/Revenue | 5.025 |
Enterprise Value/EBITDA | 16.524 |
Trading Information
Ligand Pharmaceuticals Incorporated Stock Price History
Beta (5Y Monthly) | 0.970422 |
52-Week Change | -2.056% |
S&P500 52-Week Change | 20.43% |
52 Week High | 105.15 EUR |
52 Week Low | 54.47 EUR |
50-Day Moving Average | 68 EUR |
200-Day Moving Average | 71.62 EUR |
LGDN.F Share Statistics
Avg. Volume (3 month) | 1 EUR |
Avg. Daily Volume (10-Days) | 3 EUR |
Shares Outstanding | 17.27M |
Float | 16.39M |
Short Ratio | N/A |
% Held by Insiders | 5.66% |
% Held by Institutions | 88.91% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:6 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 11.76% |
Operating Margin (ttm) | 7.41% |
Gross Margin | 58.07% |
EBITDA Margin | 30.41% |
Management Effectiveness
Return on Assets (ttm) | 0.98% |
Return on Equity (ttm) | 7.13% |
Income Statement
Revenue (ttm) | 203.71M EUR |
Revenue Per Share (ttm) | 12.03 EUR |
Quarterly Revenue Growth (yoy) | 20.39% |
Gross Profit (ttm) | 107.34M EUR |
EBITDA | 61.96M EUR |
Net Income Avi to Common (ttm) | 51.32M EUR |
Diluted EPS (ttm) | 2.76 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 282.66M EUR |
Total Cash Per Share (mrq) | 16.37 EUR |
Total Debt (mrq) | 88.68M EUR |
Total Debt/Equity (mrq) | 13.72 EUR |
Current Ratio (mrq) | 3.317 |
Book Value Per Share (mrq) | 37.721 |
Cash Flow Statement
Operating Cash Flow (ttm) | 119.79M EUR |
Levered Free Cash Flow (ttm) | 102.25M EUR |
Profile of Ligand Pharmaceuticals Incorporated
Country | Germany |
State | CA |
City | San Diego |
Address | 3911 Sorrento Valley Boulevard |
ZIP | 92121 |
Phone | 858 550 7500 |
Website | https://www.ligand.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 76 |
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in San Diego, California.
Q&A For Ligand Pharmaceuticals Incorporated Stock
What is a current LGDN.F stock price?
Ligand Pharmaceuticals Incorporated LGDN.F stock price today per share is 76 EUR.
How to purchase Ligand Pharmaceuticals Incorporated stock?
You can buy LGDN.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Ligand Pharmaceuticals Incorporated?
The stock symbol or ticker of Ligand Pharmaceuticals Incorporated is LGDN.F.
Which industry does the Ligand Pharmaceuticals Incorporated company belong to?
The Ligand Pharmaceuticals Incorporated industry is Biotechnology.
How many shares does Ligand Pharmaceuticals Incorporated have in circulation?
The max supply of Ligand Pharmaceuticals Incorporated shares is 17.71M.
What is Ligand Pharmaceuticals Incorporated Price to Earnings Ratio (PE Ratio)?
Ligand Pharmaceuticals Incorporated PE Ratio is 26.85512400 now.
What was Ligand Pharmaceuticals Incorporated earnings per share over the trailing 12 months (TTM)?
Ligand Pharmaceuticals Incorporated EPS is 2.83 EUR over the trailing 12 months.
Which sector does the Ligand Pharmaceuticals Incorporated company belong to?
The Ligand Pharmaceuticals Incorporated sector is Healthcare.